We have all been impacted by cancer – whether we know a survivor, have lost a loved one, or are living with cancer ourselves. Please know that all of us at Natera are thinking of you on World Cancer Day. We stand with you and so many others in hopes of better prevention,

Support for ctDNA testing continues to grow, with these latest updates to the NCCN clinical practice guidelines in oncology.

Really important news out of Medicare today for patients with lung cancer, one of the most common and deadly forms of cancer. Medicare coverage of Signatera in lung cancer adds to a growing list of covered indications for Signatera, and will continue to support our ability to

Today is Employee Appreciation Day, and I want to recognize our amazing team at Natera. Since joining the company in 2010, I’ve been humbled by the people at Natera and their commitment since day 1. Natera employees are focused on helping as many patients as possible.

DEFINE-HT is a novel study, in which we investigate several hypotheses with the ultimate goal of improving post-transplant care for patients. We will share the study results at ISHLT in April, which also happens to be Donate Life month. All of us at Natera are incredibly

We have more than 850 lab team members at Natera. Their work spans logistics, sample collection, accessioning, data collection, data analysis, and reporting. This is the most important work we do. Our lab professionals ensure that quality comes with both integrity and

Sarcoma is a rare and aggressive cancer with limited tools for treatment monitoring, yet it affects 17,000 people each year in the U.S. alone. That’s why we were so encouraged by the results of this Stanford-led study, which was presented at SSO, showing how personalized ctDNA

Proud to see continued progress in our efforts to transform post-transplant care for patients with our first paper published in American Journal of Transplantation. The latest data on Prospera Heart highlights the power of our unique DQS algorithm in reducing false positives and

Learn more about Signatera and the foundational technology that is transforming care for patients with cancer. Hear directly from Natera CEO Steve Chapman on how Signatera can detect molecular residual disease and help determine whether therapy is working. #CancerCare

Today we announced that Signatera Genome is covered by Medicare, an important win for patients enabling greater access to our portfolio of innovative MRD products. Thank you to our Market Access team who works so hard every day on behalf of patients with cancer. I also want to

Several Naterans in our oncology group are in Barcelona to present data at ESMO GI. This is truly impactful research within GI cancers showcasing the clinical and economic utility of Signatera, along with our latest innovations in molecular residual disease. Congrats to all

Chronic kidney disease (CKD) affects 1 in 7 adults in the U.S., and often progresses silently until it's too late to intervene effectively. As part of the American Clinical Laboratory Association' Power of Knowing series, I spoke about how renal genetic testing is transforming the way clinicians approach CKD.

WTC kicks off this weekend and this is an incredible showing for Natera at such an important global conference. We’re proud to see our technology featured in multiple presentations that reinforce our commitment to rigorous innovation and science. Thank you and congratulations to

I’m thrilled to share a major achievement for our Signatera test that represents both a scientific breakthrough and a defining moment for the field. Today, Natera announced positive topline results from the Phase III IMvigor011 trial in muscle invasive bladder cancer.

Exciting news today on our newly-announced sophisticated AI tools that we believe will accelerate diagnostic and therapeutic innovation.

This is an incredible lineup heading into ESMO. Signatera will be featured in multiple studies and we have six oral presentations. IMvigor011 was selected for a Presidential Symposium and will be discussed during the press briefing on Monday. There is also compelling evidence

Being named to Fast Company’s 2025 Next Big Things in Tech list is a proud moment for Natera. We’re honored that our Signatera test has been recognized among the top innovations in Health and Medicine. Signatera is helping redefine cancer care through personalized

This is an incredible milestone. We believe IMvigor011 offers important evidence to transform care for patients with muscle invasive bladder cancer. Published today by NEJM, this study shows how Signatera can identify which patients will benefit from adjuvant immunotherapy and

Grateful to Roelof Botha for his persistent guidance, optimism, and belief in Natera’s mission. He saw the potential early on and has been a true partner in shaping who we are today. Thank you, Roelof, for your trust, clarity and support as an esteemed member of our Board.

Today, on Genetic Counselor Appreciation Day, I want to recognize and thank the more than 150 genetic counselors at Natera who contribute to our mission in so many ways. Our GCs work across nearly every function, shaping how we communicate, teach and lead. They help